Evidence map›Paper›PMID 30176066›Full record

SynthesisJournal of the European Academy of Dermatology and Venereology : JEADV2019

Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.

C C Zouboulis, F G Bechara, J L Dickinson-Blok, W Gulliver, B Horváth, R Hughes, A B Kimball, B Kirby, A Martorell, M Podda and 7 more

Open access · hybridAbstract readConsensus StatementSystematic Review
In one paragraph

Synthesis in Journal of the European Academy of Dermatology and Venereology : JEADV, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 6 pooled it
24.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 6 syntheses or guidelines pooled it, 246 citations in OpenAlex.

  1. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.Journal of the European Academy of Dermatology and Venereology : JEADV · 2019
    Trial
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Management of penoscrotal hidradenitis: a narrative review.International journal of impotence research · 2025
    Review
  16. Article
  17. Racial Disparities in Hidradenitis Suppurativa Management at a Single Institution.Plastic and reconstructive surgery. Global open · 2025
    Article
  18. Article
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 8 countries.

C C ZouboulisDepartments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany.ORCID http://orcid.org/0000-0003-1646-2608
F G BecharaDermatologic Surgery Unit, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
J L Dickinson-BlokDepartment of Dermatology, Hospital Nij Smellinghe, Drachten, The Netherlands.
W GulliverDivision of Dermatology, Memorial University of Newfoundland, St. John's, NL, Canada.
B HorváthDepartment of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
R HughesDepartment of Dermatology, St Vincent's University Hospital, Dublin, Ireland.
A B KimballDepartment of Dermatology, Harvard Medical School, Boston, MA, USA.
B KirbyDepartment of Dermatology, St Vincent's University Hospital, Dublin, Ireland.
A MartorellDepartment of Dermatology, Hospital de Manises, Valencia, Spain.
M PoddaDepartment of Dermatology, Medical Center Klinikum Darmstadt, Darmstadt, Germany.
E P PrensDepartment of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands.
H C RingDepartment of Dermatology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark.ORCID http://orcid.org/0000-0002-6145-5549
T TzellosDepartment of Dermatology, Faculty of Health Sciences, University Hospital of North Norway, Harstad and Institute of Clinical Medicine, Arctic University, Tromsø, Norway.
H H van der ZeeDepartment of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands.
K R van StraalenDepartment of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands.
A R J V VossenDepartment of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands.
G B E JemecDepartment of Dermatology, Zealand University Hospital, University of Copenhagen, Roskilde, Denmark.
Erasmus MC · NLSt. Vincent's University Hospital · IEUniversity of Copenhagen · DKHarvard University · USHospital de Manises · ESKlinikum Darmstadt · DEMedizinische Hochschule Brandenburg Theodor Fontane · DEMemorial University of Newfoundland · CAUniversity Hospital of North Norway · NOUniversity Hospitals of the Ruhr-University of Bochum · DEUniversity Medical Center Groningen · NLZiekenhuis Nij Smellinghe · NL

Funding

AbbVieAmgenEli LillyLeo pharmaNovartisPfizer
6 · The paper itself

Abstract

Hidradenitis suppurativa (HS)/acne inversa is a debilitating chronic disease that remains poorly understood and difficult to manage. Clinical practice is variable, and there is a need for international, evidence-based and easily applicable consensus on HS management. We report here the findings of a systematic literature review, which were subsequently used as a basis for the development of international consensus recommendations for the management of patients with HS. A systematic literature review was performed for each of nine clinical questions in HS (defined by an expert steering committee), covering comorbidity assessment, therapy (medical, surgical and combinations) and response to treatment. Included articles underwent data extraction and were graded according to the Oxford Centre for Evidence-based Medicine criteria. Evidence-based recommendations were then drafted, refined and voted upon, using a modified Delphi process. Overall, 5310 articles were screened, 171 articles were analysed, and 65 were used to derive recommendations. These articles included six randomized controlled trials plus cohort studies and case series. The highest level of evidence concerned dosing recommendations for topical clindamycin in mild disease (with systemic tetracyclines for more frequent/widespread lesions) and biologic therapy (especially adalimumab) as second-line agents (following conventional therapy failure). Good-quality evidence was available for the hidradenitis suppurativa clinical response (HiSCR) as a dichotomous outcome measure in inflammatory areas under treatment. Lower-level evidence supported recommendations for topical triclosan and oral zinc in mild-to-moderate HS, systemic clindamycin and rifampicin in moderate HS and intravenous ertapenem in selected patients with more severe disease. Intralesional or systemic steroids may also be considered. Local surgical excision is suggested for mild-to-moderate HS, with wide excision for more extensive disease. Despite a paucity of good-quality data on management decisions in HS, this systematic review has enabled the development of robust and easily applicable clinical recommendations for international physicians based on graded evidence.

Indexed as

AdalimumabAnti-Bacterial AgentsAnti-Inflammatory AgentsBiological ProductsComorbidityConsensusDelphi TechniqueHidradenitis SuppurativaHumansSmokingAdalimumabAnti-Bacterial AgentsAnti-Inflammatory AgentsBiological Products

Identifiers

PMID30176066
PMCPMC6587546
OpenAlexW2890730116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.